The Rise of a New Psychoactive Agent: Salvia divinorum

Article

Abstract

Since the 1990s, there has been a rise in the availability and recreational use of a herbal plant called Salvia divinorum. Numerous internet websites have advertised it for sale as a legal herbal alternative to illegal hallucinogens. Initial data surveying use has indicated many young adults are obtaining and using this herb for its psychoactive properties. Reported methods of ingestion for the plant include chewing, and smoking leaves or fortified extracts. Subjective effects of the plant include, affect changes, psychedelic-like changes in perception, and even loss of consciousness. Although the pharmacological properties and possible antidepressant effects have been studied in recent years, little information is known about potential negative impact resulting from recreational use, and scant information about Salvia divinorum currently exists in the psychological and substance abuse literature. While Salvia divinorum appears to be a substance with some therapeutic potential, it also poses some significant dangers as a substance of varying legal status with a potential for abuse.

Keywords

Salvia divinorum Salvia Drugs of abuse Recreational drugs Hallucinogen Kappa-opioid receptor Salvinorin-A Herbal drugs 

References

  1. Baggott, M. J., Erowid, E., Erowid, F., & Mendelson, J. E. (2004). Use of salvia divinorum, an unscheduled hallucinogenic plant: A web-based survey of 500 users. Clinical Pharmacology and Therapeutics 75, 72.Google Scholar
  2. Chavkin, C., Sud, S., Jin, W., Stewart, J., Zjawiony, J. K., Siebert, D. J., et al. (2004). Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum, is a highly efficacious kappa opioid receptor agonist: Structural and functional considerations. The Journal of Pharmacology and Experimental Therapeutics, 308(3), 1197–1203.PubMedCrossRefGoogle Scholar
  3. Devine, D. P., Leone, P., Pocock, D., & Wise, R. A. (1993). Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. The Journal of Pharmacology and Experimental Therapeutics, 266, 1236–1246.PubMedGoogle Scholar
  4. Di Chiara, G., & Imperato, A. (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. The Proceedings of the National Academy of Sciences of the USA, 85, 5274–5278.CrossRefGoogle Scholar
  5. Donzanti, B. A., Althaus, J. S., Payson, M. M., & Von Voigtlander, P. F. (1992). Kappa agonist-induced reduction in dopamine release: Site of action and tolerance. Research Communications in Chemical Pathology and Pharmacology, 78, 193–210.PubMedGoogle Scholar
  6. Drug Enforcement Administration. (2007). List of drugs and chemicals of concern. Internet website: http://www.deadiversion.usdoj.gov/drugs_concern/salvia_d/salvia_d.htm.
  7. Epling, C., & Játiva-M, C. D. (1962). A new species of salvia from Mexico. Botanical Museum. Leaflets Harvard University, 20, 75–76.Google Scholar
  8. Glick, S. D., Maisonneuve, I. M., Raucci, J., & Archer S. (1995). Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Research, 681, 147–152.PubMedCrossRefGoogle Scholar
  9. González, D., Riba, J., Bouso, J. C., Gómez-Jarabo, G., & Barbanoj, M. J. (2006). Pattern of use and subjective effects of salvia divinorum among recreational users. Drug and Alcohol Dependence, 85(2), 157–162.PubMedCrossRefGoogle Scholar
  10. Haynes, K. R. (2001). Antidepressant effects of the herb salvia divinorum: A case report. Journal of Clinical Psychopharmacology, 21(6), 634–635.CrossRefGoogle Scholar
  11. Kuzmin, A. V., Semenova, S., Gerrits, M., Zvartau, E. E., & Van Ree, J. M. (1997). K-Opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naïve rats and mice. European Journal of Pharmacology, 321, 265–271.PubMedCrossRefGoogle Scholar
  12. Prisinzano, T. E. (2005). Psychopharmacology of the hallucinogenic sage salvia divinorum. Life Sciences, 78(5), 527–531.PubMedGoogle Scholar
  13. Rey, J, & Tennant, C. (2002). Cannabis and mental health. British Medical Journal, 325, 1183–1184.PubMedCrossRefGoogle Scholar
  14. Roth, B. L., Baner, K., Westkaemper, R., Siebert, D., Rice, K. C., Steinberg, S., Ernsberger, P., & Rothman R. B. (2002). Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proceedings of the National Academy of Sciences of the USA, 99(18), 11934–11939.PubMedCrossRefGoogle Scholar
  15. Schaper D. (2006). National Public Radio: Legal, herbal hallucinogenic draws teens, critics. Radio broadcast Washington, DC: NPR.Google Scholar
  16. Schenk, S., Partridge, B., & Shippenberg, T. S. (1999). U69593, a kappaopioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology, 144, 339–346.PubMedCrossRefGoogle Scholar
  17. Sheffler, D. J., & Roth, B. L. (2003). Salvinorin A: The ‘magic mint’ hallucinogen finds a molecular target in the kappa opioid receptor. Trends in Pharmacological Sciences, 24(3), 107–109.PubMedCrossRefGoogle Scholar
  18. Siebert, D. (1994). Salvia divinorum and salvinorin A: New pharmacologic findings. Journal of Ethnopharmacology, 43, 53–56.PubMedCrossRefGoogle Scholar
  19. Spanagel, R., Herz, A., & Shippenberg, T. S. (1992). Opposing tonically active endogeneous opioid systems modulate the mesolimbic dopaminergic pathway. Proceedings of the National Academy of Sciences of the USA, 89, 2046–2050.PubMedCrossRefGoogle Scholar
  20. Ukai, M., Suzuki, M., & Mamiya, T. (2002). Effects of U-50, 488H, a kappa opioid receptor agonist, on the learned helplessness model of depression in mice. Journal of Neural Transmission, 109, 1221–1225.PubMedCrossRefGoogle Scholar
  21. Valdés, L. J. III (1994). Salvia divinorum and the unique diterpene hallucinogen, salvinorin (divinorin) A. Journal of Psychoactive Drugs, 26, 277–283.PubMedGoogle Scholar
  22. Valdes, L. J. III, Diaz, J., & Paul, A. G. (1983). Ethnopharmacology of ska maria pastora (Salvia divinorum, Epling and Játiva-M.). Journal of Ethnopharmacology, 7, 287–312.PubMedCrossRefGoogle Scholar
  23. Valdes, L. J. III, Butler, W. B., Hatfield, G. M., Paul, A. G., & Koreeda M. (1984). Divinorin A, a psychotropic terpenoid, and divinorin B from the hallucinogenic Mexican mint, salvia divinorum. Journal of Organic Chemistry, 49, 4716–4720.CrossRefGoogle Scholar
  24. Walsh, S. K., Geter-Douglas, B., Strain, E. C., Bigelow, G. E. (2001). Enadoline and butorphanol: Evaluation of k-agonist on cocaine pharmacodynamics and cocaine self-administration in humans. Pharmacology, 299, 147–158.Google Scholar
  25. Wasson, R. G. (1962). A new Mexican psychotropic drug from the mint family. Botanical Museum Leaflets Harvard University, 20, 77–84.Google Scholar
  26. Wasson, R. G. (1963). Notes on the present status of ololiuhqui and the other hallucinogens of Mexico. Botanical Museum Leaflets Harvard University, 20, 161–193.Google Scholar
  27. Zhang, Y., Butelman, E. R., Schlussman, S. D., Ho, A., & Kreek, M. J. (2005). Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: Agonist actions at kappa opioid receptors. Psychopharmacology, 179, 551–558.PubMedCrossRefGoogle Scholar
  28. Zhang, Y., Butelman, E. R., Schlussman, S. D., Ho, A., & Kreek, M. J. (2004). Effect of the k- opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. Psychopharmacology, 173, 146–152.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Department of Behavioral and Social SciencesTiffin UniversityTiffinUSA
  2. 2.Firelands Counseling and Recovery ServicesTiffinUSA

Personalised recommendations